Insmed Incorporated (INSM) income statement
NASDAQ · Healthcare · Biotechnology · 1,664 employees · CEO William H. Lewis
- Price
- $112.58 +0.89%
- Market cap
- $24.7B
- Enterprise value
- $25B
- Last report
- Q3 '26 filed 2026-10-29
- Next report
- 2027-02-18 EPS est. -$0.32
Insmed Incorporated (INSM) reported revenue of $524M for Q3 '26 (+268.4% year on year), operating income of -$89.4M (-17.0% of revenue) and net income of -$100M. Over the last four quarters revenue was $1.52B.
Income statement
| Income statement | Trend | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $83.7M | $75.5M | $90.3M | $93.4M | $104M | $92.8M | $107M | $142M | $264M | $306M | $425M | $524M | |
| Cost of revenue | $18.4M | $17.5M | $21M | $21.2M | $26.2M | $21.3M | $28.1M | $29.4M | $44.2M | $49.5M | $67.2M | $78.2M | |
| Gross profit | $65.3M | $58M | $69.4M | $72.3M | $78.3M | $71.5M | $79.3M | $113M | $220M | $256M | $358M | $446M | |
| Research & development | $137M | $121M | $147M | $151M | $180M | $153M | $177M | $186M | $255M | $209M | $210M | $270M | |
| General & administrative | $89.5M | $93.1M | $107M | $119M | $143M | $148M | $155M | $186M | $212M | $0 | $247M | $253M | |
| Other operating expenses | $17M | -$10.6M | $105M | $15.9M | -$13.5M | $19.6M | $60.3M | $106M | $1.94M | $0 | -$97.7M | $12.6M | |
| Operating expenses | $244M | $204M | $358M | $286M | $309M | $320M | $392M | $479M | $469M | $457M | $360M | $536M | |
| Operating income | -$178M | -$146M | -$289M | -$213M | -$230M | -$248M | -$313M | -$366M | -$250M | -$200M | -$1.55M | -$89.4M | |
| Interest income | $9.85M | $8.78M | $10.3M | $17M | $17.3M | $13.9M | $13.2M | $18.3M | $15.2M | $12M | $0 | $11.1M | |
| Interest expense | $20.8M | $21M | $21.3M | $21.1M | $21.6M | $21.6M | $21.2M | $20.4M | $20.6M | $20.1M | $20.3M | $20.4M | |
| Other non-operating income (gains on investments, FX ...) | -$13M | -$8.95M | -$9.31M | -$14.3M | -$15.9M | -$12.2M | -$12M | -$16.3M | $58M | -$58.3M | -$10.4M | -$12.1M | |
| Total non-operating income | -$6.79M | -$11M | -$10.9M | -$6.08M | -$3.87M | -$7.53M | -$7.57M | -$2.7M | -$77.2M | $38.2M | -$9.83M | -$8.28M | |
| Income before tax | -$185M | -$157M | -$300M | -$220M | -$234M | -$256M | -$320M | -$369M | -$327M | -$162M | -$11.4M | -$97.7M | |
| Income tax | $998K | $589K | $838K | $1.01M | $1.27M | $912K | $1.24M | $1.32M | $1.55M | $1.47M | $1.87M | $2.67M | |
| Net income | -$186M | -$157M | -$301M | -$221M | -$236M | -$257M | -$322M | -$370M | -$328M | -$164M | -$13.2M | -$100M | |
| EPS (basic) | -$1.28 | -$1.06 | -$1.94 | -$1.27 | -$1.32 | -$1.42 | -$1.70 | -$1.75 | -$1.54 | -$0.76 | -$0.06 | -$0.46 | |
| EPS (diluted) | -$1.28 | -$1.06 | -$1.94 | -$1.27 | -$1.32 | -$1.42 | -$1.70 | -$1.75 | -$1.54 | -$0.76 | -$0.06 | -$0.46 | |
| Shares (basic, weighted) | 145M | 148M | 155M | 174M | 179M | 181M | 189M | 211M | 214M | 215M | 217M | 219M | |
| Shares (diluted, weighted) | 145M | 148M | 155M | 174M | 179M | 181M | 189M | 211M | 214M | 215M | 217M | 219M | |
| Depreciation & amortization | $2.74M | $2.85M | $2.7M | $2.72M | $2.74M | $3.15M | $3.75M | $4M | $5.56M | $4.92M | $5.26M | $8.4M | |
| EBITDA | -$163M | -$134M | -$277M | -$196M | -$212M | -$233M | -$297M | -$346M | -$302M | -$137M | $14.2M | -$68.8M |
| Income statement | Trend | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $9.84M | $136M | $164M | $188M | $245M | $305M | $364M | $606M | |
| Cost of revenue | $2.44M | $2.9M | $2.42M | $24.2M | $39.9M | $44.2M | $55.1M | $65.6M | $85.7M | $125M | |
| Gross profit | -$2.44M | -$2.9M | $7.41M | $112M | $125M | $144M | $190M | $240M | $278M | $482M | |
| Research & development | $123M | $110M | $145M | $132M | $181M | $273M | $398M | $571M | $598M | $771M | |
| General & administrative | $50.7M | $79.2M | $168M | $211M | $204M | $234M | $266M | $345M | $461M | $701M | |
| Other operating expenses | $119K | $300K | $1.25M | $4.99M | $5M | $12.4M | -$15.7M | $33.7M | $96.7M | $186M | |
| Operating expenses | $173M | $189M | $315M | $348M | $390M | $519M | $648M | $949M | $1.16B | $1.66B | |
| Operating income | -$173M | -$189M | -$307M | -$235M | -$265M | -$375M | -$457M | -$710M | -$878M | -$1.18B | |
| Interest income | $604K | $1.62M | $10.3M | $9.92M | $1.7M | $174K | $11.1M | $42.1M | $53.3M | $60.7M | |
| Interest expense | $3.5M | $5.93M | $25.5M | $27.7M | $29.6M | $40.5M | $26.4M | $81.7M | $84.9M | $83.8M | |
| Other non-operating income (gains on investments, FX ...) | -$723K | -$1.92M | -$7.33M | -$7.99M | -$711K | $22.7M | $375K | -$38.9M | -$48.4M | $11.2M | |
| Total non-operating income | -$2.78M | -$4M | -$16.7M | -$18.3M | -$27.5M | -$61.3M | -$22.8M | -$37.4M | -$31.8M | -$95M | |
| Income before tax | -$176M | -$193M | -$324M | -$254M | -$293M | -$436M | -$480M | -$747M | -$910M | -$1.27B | |
| Income tax | $98K | -$272K | $201K | $777K | $1.4M | -$1.76M | $1.38M | $2.56M | $3.71M | $5.03M | |
| Net income | -$176M | -$193M | -$324M | -$254M | -$294M | -$435M | -$482M | -$750M | -$914M | -$1.28B | |
| EPS (basic) | -$2.85 | -$2.89 | -$4.22 | -$3.01 | -$3.01 | -$3.88 | -$3.91 | -$5.34 | -$5.57 | -$6.41 | |
| EPS (diluted) | -$2.85 | -$2.89 | -$4.22 | -$3.01 | -$3.01 | -$3.88 | -$3.91 | -$5.34 | -$5.57 | -$6.41 | |
| Shares (basic, weighted) | 61.9M | 66.6M | 76.8M | 84.6M | 97.6M | 112M | 123M | 140M | 164M | 214M | |
| Shares (diluted, weighted) | 61.9M | 66.6M | 76.9M | 84.6M | 97.6M | 112M | 123M | 140M | 164M | 214M | |
| Depreciation & amortization | $2.44M | $2.9M | $4.83M | $10.2M | $14.2M | $14.2M | $10.3M | $10.6M | $11M | $16.5M | |
| EBITDA | -$170M | -$184M | -$295M | -$217M | -$250M | -$384M | -$447M | -$660M | -$819M | -$1.17B |
Standardised from the company's filings; outflows and costs keep the sign the provider reports. Hover a period for its end date. Amounts in USD.
Revenue, operating income and growth
quarterlyMargins
quarterlyCosts as % of revenue
quarterlyThe other statements
Sources
Statements, segment revenue, metrics and estimates are standardised from the company's filings. Segment profits and every reported line: SEC EDGAR (XBRL). Filings read: 10-Q 2026-09-30, 10-Q 2026-06-30, 10-Q 2026-03-31, 10-K 2025-12-31, 10-Q 2025-09-30, 10-Q 2025-06-30, 10-Q 2025-03-31, 10-K 2024-12-31, 10-Q 2024-09-30
Data as of 2026-11-02